Maarten van der Doelen

Actinium-225 labeled PSMA radioligand therapy in mCRPC patients

Supplementary table 2. Radiological evaluation according to RECIST 1.1, PERCIST, and semi-automated whole body tumor volume measurements.

SUV max target lesion response (%)

Tumor volume response (%)

ID RECIST response PERCIST response

01 PR

PR

-82.4

-95.2

02 PR

PR

-53.9

-93.0

2

03 NA

PR

-83.5

-91.5

04* SD

NE

NE

NE

05 NE

NE

NE

NE

06 NA

PR

-79.9

-100.0

07 PR

PR

-96.5

-100.0

08 PD

PD

-100.0

-94.3

09 NE

NE

NE

NE

10 NE

NE

NE

NE

11 NA

PR

-79.2

-99.9

12 NE

NE

NE

NE

13 PD NE CT = computer tomography; NA = not applicable (no target lesions at baseline CT); NE = not evaluated (no follow up scan available); PD = progressive disease; PR = partial response; SD = stable disease; SUV = standardized uptake value. * Patient ID 04 underwent only CT thorax/abdomen after 225 Ac-PSMA-617 TAT. NE NE

47